Compare PLSE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | MESO |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2015 | N/A |
| Metric | PLSE | MESO |
|---|---|---|
| Price | $28.58 | $16.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 329.0K | 220.4K |
| Earning Date | 05-07-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $840.00 | $629.74 |
| Revenue Next Year | $287.54 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.56 | $12.66 |
| 52 Week High | $31.00 | $21.50 |
| Indicator | PLSE | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 58.87 |
| Support Level | $23.94 | $13.82 |
| Resistance Level | $31.00 | $17.33 |
| Average True Range (ATR) | 1.58 | 0.66 |
| MACD | -0.05 | 0.30 |
| Stochastic Oscillator | 70.14 | 53.53 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.